Lorenz J, Moghanaki D, Keshava H, Harpole D H, Bradley J D, Higgins K A, Rusthoven C G, Stokes W A
Winship Cancer Institute, Department of Radiation Oncology, Emory University, Atlanta, GA, United States; Emory University, Atlanta, GA, United States.
Atlanta Veterans Affairs Health Care System, Atlanta, GA, United States; Emory University, Atlanta, GA, United States.
Lung Cancer. 2023 Jan;175:57-59. doi: 10.1016/j.lungcan.2022.11.011. Epub 2022 Nov 19.
Patients receiving stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) are typically inoperable, in concordance with guidelines that advocate surgical resection as preferred treatment for operable patients. This differential treatment allocation complicates retrospective comparisons of surgery with SBRT by introducing the potential for confounding by operability.
PubMed was queried for manuscripts reporting primary data from retrospective comparisons of overall survival (OS) between patients undergoing surgery versus SBRT for early-stage NSCLC. Each manuscript was categorized for two outcomes: (1) whether treatment allocation was based on a determination of patient operability, and (2) whether a direct OS comparison between operable SBRT patients and surgically treated patients was included. Associations with variables of interest were measured with statistical significance prespecified at p < 0.10.
From 3,072 manuscripts identified in our query, sixty-one analyses met screening criteria. Twenty-one (34 %) reported operability status influencing treatment allocation. These were more likely to be published in journals with a surgical focus (52 vs 20 %) and impact factor < 5 (81 vs 58 %), and to contain cohorts from institutional datasets (81 vs 55 %), and to have a radiation oncologist as first (43 vs 25 %) or senior (43 vs 28 %) author. Seven (11 %) manuscripts featured a direct OS comparison between SBRT and surgery.
Nearly-two-thirds of peer-reviewed retrospective studies that have compared OS between surgery and SBRT for early-stage NSCLC lack information on patient operability status, and nearly 90% lack a direct comparison between operable SBRT patients and those receiving surgery.
对于早期非小细胞肺癌(NSCLC)患者,接受立体定向体部放疗(SBRT)的患者通常无法进行手术,这与主张手术切除为可手术患者首选治疗方法的指南一致。这种不同的治疗分配方式因引入了可手术性导致的混杂因素,使手术与SBRT的回顾性比较变得复杂。
在PubMed上查询报告早期NSCLC患者接受手术与SBRT的总体生存(OS)回顾性比较的原始数据的手稿。每篇手稿按两个结果分类:(1)治疗分配是否基于患者可手术性的判定;(2)是否包括可手术的SBRT患者与接受手术治疗患者之间的直接OS比较。通过将统计学显著性预先设定为p<0.10来衡量与感兴趣变量的关联。
在我们查询到的3072篇手稿中,61项分析符合筛选标准。21项(34%)报告了可手术性状态影响治疗分配。这些更有可能发表在以手术为重点的期刊上(52%对20%),影响因子<5(81%对58%),包含来自机构数据集的队列(81%对55%),并且第一作者(43%对25%)或资深作者(43%对28%)为放射肿瘤学家。7项(11%)手稿对SBRT和手术进行了直接OS比较。
在对早期NSCLC患者手术与SBRT的OS进行比较的同行评审回顾性研究中,近三分之二缺乏患者可手术性状态的信息,近90%缺乏可手术的SBRT患者与接受手术患者之间的直接比较。